Evaluation of the omission of dexamethasone in premedication regimens during paclitaxel treatment
- Conditions
- Solid tumorsTherapeutic area: Diseases [C] - Neoplasms [C04]
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 500
Age =18 years, Diagnosis of a solid tumor with planned treatment with paclitaxel-based chemotherapy for any indication and with any dose., Mastery of Dutch language, Able and willing to give written informed consent.
Prior treatment with a paclitaxel-based regimen;, An indication for paclitaxel in combination with moderately or highly emetogenic chemotherapy that mandates the use of dexamethasone as an anti-emetic medication (e.g., carboplatin AUC>4);, Known hypersensitivity to paclitaxel, carboplatin, cetirizine, or excipients (e.g., benzyl alcohol);, Concomitant use of any systemic corticosteroid for any indication other than paclitaxel premedication;, Women with confirmed and ongoing pregnancy;, Already participating in an exercise trial.
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method